Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
Vikas A Gupta, Ajay K Nooka, Sagar Lonial, Lawrence H BoiseDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USAAbstract: Treatment of refractory and/or relapsed multiple myeloma has been a challenging problem for over 20 years...
Guardado en:
Autores principales: | Gupta VA, Nooka AK, Lonial S, Boise LH |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d4e75dca93aa4addb989dbed6c00bdd2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS
por: Mehmut TURGUT, et al.
Publicado: (2021) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
por: Illidge T, et al.
Publicado: (2012) -
TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Ebru Pekgüç, et al.
Publicado: (2021) -
Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu YC, et al.
Publicado: (2014)